382 related articles for article (PubMed ID: 12142386)
1. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
[TBL] [Abstract][Full Text] [Related]
2. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
3. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
[TBL] [Abstract][Full Text] [Related]
5. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
Ramón L; Gilabert-Estellés J; Castelló R; Gilabert J; España F; Romeu A; Chirivella M; Aznar J; Estellés A
Hum Reprod; 2005 Jan; 20(1):272-8. PubMed ID: 15579491
[TBL] [Abstract][Full Text] [Related]
6. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
7. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
8. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
9. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B
Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Benassi MS; Ponticelli F; Azzoni E; Gamberi G; Pazzaglia L; Chiechi A; Conti A; Spessotto P; Scapolan M; Pignotti E; Bacchini P; Picci P
Histol Histopathol; 2007 Sep; 22(9):1017-24. PubMed ID: 17523079
[TBL] [Abstract][Full Text] [Related]
12. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
13. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression.
Martens JW; Sieuwerts AM; Bolt-deVries J; Bosma PT; Swiggers SJ; Klijn JG; Foekens JA
Thromb Haemost; 2003 Feb; 89(2):393-404. PubMed ID: 12574821
[TBL] [Abstract][Full Text] [Related]
14. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Schrohl AS; Holten-Andersen MN; Peters HA; Look MP; Meijer-van Gelder ME; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 2004 Apr; 10(7):2289-98. PubMed ID: 15073104
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Look MP; van Putten WL; Duffy MJ; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder ME; Manders P; Fiets WE; Blankenstein MA; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex LV; Klijn JG; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens JA
J Natl Cancer Inst; 2002 Jan; 94(2):116-28. PubMed ID: 11792750
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer.
Spyratos F; Bouchet C; Tozlu S; Labroquere M; Vignaud S; Becette V; Lidereau R; Bieche I
Anticancer Res; 2002; 22(5):2997-3003. PubMed ID: 12530032
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
[TBL] [Abstract][Full Text] [Related]
18. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
20. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]